The historical rank and industry rank for Noile-Immune Biotech's Gross Margin % or its related term are showing as below:
TSE:4893'
s Gross Margin % Range Over the Past 10 Years
Min: 77.27 Med: 97.91 Max: 99.55
Current: 99.55
During the past 4 years, the highestGross Margin % of Noile-Immune Biotech was 99.55%. The lowest was 77.27%. And the median was 97.91%.
TSE:4893's Gross Margin % is ranked better than 97.73% of 748
companies
in the Biotechnology industry
Industry Median: 59.99
vs TSE:4893: 99.55
Noile-Immune Biotech had a gross margin of 92.46% for the quarter that ended in Mar. 2024 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Noile-Immune Biotech was 0.00% per year.
Noile-Immune Biotech Gross Margin % Historical Data
The historical data trend for Noile-Immune Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Noile-Immune Biotech's Gross Margin %
For the Biotechnology subindustry, Noile-Immune Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noile-Immune Biotech's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Noile-Immune Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Noile-Immune Biotech had a gross margin of 92.46% for the quarter that ended in Mar. 2024 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Noile-Immune Biotech Gross Margin % Related Terms
Thank you for viewing the detailed overview of Noile-Immune Biotech's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Noile-Immune Biotech (TSE:4893) Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSE:4893 has been successfully added to your 